$TBPH
Theravance Biopharma Inc

2019 Q2 Form 10-Q Financial Statement

#000155837019007084 Filed on August 05, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2 2018 Q1
Revenue $26.15M $23.48M $8.319M
YoY Change 11.39% 570.74% 168.35%
Cost Of Revenue -$1.400M $800.0K
YoY Change -200.0% 33.33%
Gross Profit $24.90M $7.500M
YoY Change 1085.71% 200.0%
Gross Profit Margin 106.07% 90.16%
Selling, General & Admin $22.23M $25.01M $24.70M
YoY Change -11.12% 2.91% 18.75%
% of Gross Profit 100.43% 329.33%
Research & Development $46.40M $48.62M $47.80M
YoY Change -4.57% 13.34% 17.73%
% of Gross Profit 195.27% 637.33%
Depreciation & Amortization $1.550M $790.0K $900.0K
YoY Change 96.2% -19.39% -16.67%
% of Gross Profit 3.17% 12.0%
Operating Expenses $68.63M $72.18M $73.30M
YoY Change -4.92% 7.41% 19.57%
Operating Profit -$42.48M -$48.70M -$64.98M
YoY Change -12.79% -25.19% 10.5%
Interest Expense $7.901M $2.137M $0.00
YoY Change 269.72% -405.29% -100.0%
% of Operating Profit
Other Income/Expense, Net $2.374M $1.284M
YoY Change 84.89%
Pretax Income -$39.64M -$47.61M -$64.90M
YoY Change -16.74% -27.65% 8.35%
Income Tax $201.0K -$6.790M $100.0K
% Of Pretax Income
Net Earnings -$39.84M -$40.82M -$65.09M
YoY Change -2.4% -38.43% -0.33%
Net Earnings / Revenue -152.34% -173.87% -782.39%
Basic Earnings Per Share
Diluted Earnings Per Share -$717.1K -$758.4K -$1.221M
COMMON SHARES
Basic Shares Outstanding 56.41M 54.96M
Diluted Shares Outstanding 55.53M 53.80M

Balance Sheet

Concept 2019 Q2 2018 Q2 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $396.1M $352.9M $418.5M
YoY Change 12.23% -2.46% 6.54%
Cash & Equivalents $178.3M $103.9M $125.8M
Short-Term Investments $217.8M $249.0M $292.7M
Other Short-Term Assets $8.900M $8.600M $6.300M
YoY Change 3.49% 100.0% -4.55%
Inventory $17.90M $17.20M
Prepaid Expenses
Receivables $111.0K $7.300M $4.800M
Other Receivables $20.00M $0.00 $0.00
Total Short-Term Assets $426.0M $386.7M $446.8M
YoY Change 10.17% 0.47% 6.0%
LONG-TERM ASSETS
Property, Plant & Equipment $12.66M $10.70M $10.30M
YoY Change 18.34% 22.99% 24.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $18.30M $17.00M
YoY Change -87.33% -89.1%
Other Assets $1.388M $2.600M $2.600M
YoY Change -46.62% -55.93% 8.33%
Total Long-Term Assets $66.41M $34.70M $33.30M
YoY Change 91.38% -78.18% -80.0%
TOTAL ASSETS
Total Short-Term Assets $426.0M $386.7M $446.8M
Total Long-Term Assets $66.41M $34.70M $33.30M
Total Assets $492.4M $421.4M $480.1M
YoY Change 16.86% -22.52% -18.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.501M $3.600M $5.100M
YoY Change -2.75% -43.75% 41.67%
Accrued Expenses $51.00M $35.40M $49.90M
YoY Change 44.07% -30.04% 10.4%
Deferred Revenue $43.31M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.30M
YoY Change
Total Short-Term Liabilities $110.1M $93.50M $105.2M
YoY Change 17.79% 63.75% 114.69%
LONG-TERM LIABILITIES
Long-Term Debt $443.1M $224.3M $224.0M
YoY Change 97.55% 0.49% 0.49%
Other Long-Term Liabilities $14.46M $69.20M $87.50M
YoY Change -79.11% 208.93% 294.14%
Total Long-Term Liabilities $14.46M $293.5M $311.5M
YoY Change -95.07% 19.5% 27.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $110.1M $93.50M $105.2M
Total Long-Term Liabilities $14.46M $293.5M $311.5M
Total Liabilities $124.6M $387.0M $416.7M
YoY Change -67.81% 27.81% 41.69%
SHAREHOLDERS EQUITY
Retained Earnings -$1.125B
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$137.2M $34.39M $63.41M
YoY Change
Total Liabilities & Shareholders Equity $492.4M $421.4M $480.1M
YoY Change 16.86% -22.52% -18.35%

Cashflow Statement

Concept 2019 Q2 2018 Q2 2018 Q1
OPERATING ACTIVITIES
Net Income -$39.84M -$40.82M -$65.09M
YoY Change -2.4% -38.43% -0.33%
Depreciation, Depletion And Amortization $1.550M $790.0K $900.0K
YoY Change 96.2% -19.39% -16.67%
Cash From Operating Activities -$48.03M -$61.54M $49.83M
YoY Change -21.95% 38.23% -199.6%
INVESTING ACTIVITIES
Capital Expenditures -$580.0K -$1.100M -$2.770M
YoY Change -47.27% 48.65% 369.49%
Acquisitions
YoY Change
Other Investing Activities -$720.0K $43.05M -$8.520M
YoY Change -101.67% 261.16% -93.07%
Cash From Investing Activities -$1.300M $41.96M -$11.29M
YoY Change -103.1% 275.65% -90.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.400M -2.400M -1.680M
YoY Change -283.33% -179.21% 37.7%
NET CHANGE
Cash From Operating Activities -48.03M -61.54M 49.83M
Cash From Investing Activities -1.300M 41.96M -11.29M
Cash From Financing Activities 4.400M -2.400M -1.680M
Net Change In Cash -44.93M -21.98M 36.86M
YoY Change 104.41% -27.51% -121.09%
FREE CASH FLOW
Cash From Operating Activities -$48.03M -$61.54M $49.83M
Capital Expenditures -$580.0K -$1.100M -$2.770M
Free Cash Flow -$47.45M -$60.44M $52.60M
YoY Change -21.49% 38.05% -206.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0001583107
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56637000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55681000
CY2019Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
11869000
CY2019Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherAccruedLiabilitiesCurrent
CY2019Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OperatingLeaseLiabilityNoncurrent
CY2019Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OperatingLeaseRightOfUseAsset
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36033
dei Entity Registrant Name
EntityRegistrantName
THERAVANCE BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
KY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1226628
dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 309
dei Entity Address Address Line2
EntityAddressAddressLine2
Ugland House, South Church Street
dei Entity Address City Or Town
EntityAddressCityOrTown
George Town, Grand Cayman
dei Entity Address Country
EntityAddressCountry
KY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
KY1-1104
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
808-6000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Ordinary Share $0.00001 Par Value
dei Trading Symbol
TradingSymbol
TBPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56637038
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178311000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
378021000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
217761000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
127255000
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
111000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
620000
CY2019Q2 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
979000
CY2018Q4 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
10053000
CY2019Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
20019000
CY2018Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
5422000
CY2019Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
8857000
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
11452000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
426038000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
532823000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12662000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13176000
CY2018Q4 tbph Non Recourse Debt Noncurrent
NonRecourseDebtNoncurrent
229535000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
7976000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48565000
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13444000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3501000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9028000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23495000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23803000
CY2019Q2 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
7404000
CY2019Q2 tbph Non Recourse Debt Noncurrent
NonRecourseDebtNoncurrent
217715000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47831000
CY2019Q2 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
3695000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
833000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
833000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1388000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1534000
CY2019Q2 us-gaap Assets
Assets
492447000
CY2018Q4 us-gaap Assets
Assets
560235000
CY2018Q4 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
11876000
CY2019Q2 us-gaap Interest Payable Current
InterestPayableCurrent
5758000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3086000
CY2019Q2 tbph Non Recourse Debt Current
NonRecourseDebtCurrent
12348000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7887000
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
43311000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
43402000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6432000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7359000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
110136000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
98554000
CY2019Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
225354000
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
224818000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
26179000
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14457000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
24762000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56637000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55681000
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
987209000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
960721000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
129000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-166000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1124563000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1012145000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-137224000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-51589000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
492447000
us-gaap Operating Expenses
OperatingExpenses
145475000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
295000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
560235000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26150000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23476000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31488000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31795000
CY2018Q2 tbph Adjusted Cost Of Goods And Services Sold
AdjustedCostOfGoodsAndServicesSold
-1448000
tbph Adjusted Cost Of Goods And Services Sold
AdjustedCostOfGoodsAndServicesSold
-622000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46399000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48621000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100217000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96386000
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22227000
CY2018Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25007000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47413000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
49711000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
68626000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
72180000
us-gaap Operating Expenses
OperatingExpenses
147630000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-42476000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-48704000
us-gaap Operating Income Loss
OperatingIncomeLoss
-116142000
us-gaap Operating Income Loss
OperatingIncomeLoss
-113680000
CY2019Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
8366000
CY2018Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1949000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
14595000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2635000
CY2019Q2 us-gaap Interest Expense
InterestExpense
7901000
CY2018Q2 us-gaap Interest Expense
InterestExpense
2137000
us-gaap Interest Expense
InterestExpense
15759000
us-gaap Interest Expense
InterestExpense
4274000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2374000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1284000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5169000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2768000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39637000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47608000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112137000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112551000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
201000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6790000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
281000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6646000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-39838000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-40818000
us-gaap Net Income Loss
NetIncomeLoss
-112418000
us-gaap Net Income Loss
NetIncomeLoss
-105905000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
165000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
329000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-137224000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-51589000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2605000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23519000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2545000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2181000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
295000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
208000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39673000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40489000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-112123000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-105697000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.98
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55529000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53799000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55235000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53529000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11298000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13855000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23519000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27853000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-113252000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2605000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11298000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2292000
CY2019Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
494000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
165000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-39838000
us-gaap Net Income Loss
NetIncomeLoss
-112418000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-137224000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
63407000
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2742000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13871000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
46000
CY2018Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5190000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
329000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-40818000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
34387000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
115178000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2742000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27869000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
1119000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6905000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
208000
us-gaap Net Income Loss
NetIncomeLoss
-105905000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
34387000
us-gaap Net Income Loss
NetIncomeLoss
-112418000
us-gaap Net Income Loss
NetIncomeLoss
-105905000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2867000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2126000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
1696000
tbph Inventoryfirmpurchasecommitmentreversalofexpense
Inventoryfirmpurchasecommitmentreversalofexpense
2250000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2016000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
14595000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
1633000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-53000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-3002000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-12826000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
88256000
tbph Increase Decrease In Lease Liabilities Noncurrent
IncreaseDecreaseInLeaseLiabilitiesNoncurrent
-1371000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
269000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
436000
us-gaap Share Based Compensation
ShareBasedCompensation
23519000
us-gaap Share Based Compensation
ShareBasedCompensation
27853000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
21000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-389000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1181000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-9074000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-3244000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
2407000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-5144000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129223000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11712000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
2963000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
351000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
3700000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-5092000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
41000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5491000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2311000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15580000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-19049000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2672000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1796000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3865000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
208028000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
101912000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
131368000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
136428000
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
5000000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
17000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73456000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30668000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2605000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2742000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2545000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
81000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2181000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6905000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2969000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4082000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-199710000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14874000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
378854000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89813000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179144000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104687000
CY2019Q2 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
0
us-gaap Interest Paid Net
InterestPaidNet
11753000
us-gaap Interest Paid Net
InterestPaidNet
3738000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
21000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-4455000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
49847000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'inherit';font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;"><span style="font-family:'inherit';">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
us-gaap Lease Practical Expedient Use Of Hindsight
LeasePracticalExpedientUseOfHindsight
true
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-39838000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-40818000
us-gaap Net Income Loss
NetIncomeLoss
-112418000
us-gaap Net Income Loss
NetIncomeLoss
-105905000
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56407000
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54958000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56114000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54763000
CY2019Q2 tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeitureincremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureincrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-878000
CY2018Q2 tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeitureincremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureincrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-1159000
tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeitureincremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureincrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-879000
tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeitureincremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureincrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-1234000
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55529000
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53799000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55235000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53529000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.98
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14144000
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12063000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12903000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11302000
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7492000
CY2018Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
16000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
12825000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
32000
CY2018Q1 tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.67
tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.65
CY2019Q2 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
815000
CY2018Q2 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
1395000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
2429000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
3245000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178311000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103854000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
833000
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
833000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179144000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104687000
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
367178000
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
162000
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
33000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
367307000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
501837000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
174000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
501671000
tbph Marketable Securities Maximum Contractual Maturity Period
MarketableSecuritiesMaximumContractualMaturityPeriod
P1Y
tbph Marketable Securities Average Contractual Maturity Period
MarketableSecuritiesAverageContractualMaturityPeriod
P3M
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2018Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2019Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2019Q2 tbph Area Of Leased Space
AreaOfLeasedSpace
170000
tbph Number Of Building Leased
NumberOfBuildingLeased
2
CY2019Q2 us-gaap Tenant Improvements
TenantImprovements
15800000
tbph Number Of Options To Extend
NumberOfOptionsToExtend
2
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47831000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7887000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48565000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
56452000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11298000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13855000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23519000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27853000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
2614000
us-gaap Operating Lease Cost
OperatingLeaseCost
5396000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4408000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7253000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9492000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9757000
tbph Number Of Tranches For Recognition Of Share Based Compensation Expenses
NumberOfTranchesForRecognitionOfShareBasedCompensationExpenses
3
tbph Number Of Performance Milestones For Recognition Of Share Based Compensation Expenses
NumberOfPerformanceMilestonesForRecognitionOfShareBasedCompensationExpenses
2
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
10035000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
70208000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
111153000
CY2019Q2 us-gaap Tenant Improvements
TenantImprovements
15774000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
38927000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
56452000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1700000
us-gaap Operating Lease Payments
OperatingLeasePayments
3800000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y8M12D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0865
CY2019Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.85
CY2019Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-200000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-300000
CY2019Q2 us-gaap Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries
DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
0
tbph Offshore Recipients Intangible Property Uk Tax Rate
OffshoreRecipientsIntangiblePropertyUKTaxRate
0.20
CY2017Q4 tbph Adjusted Cost Of Goods And Services Sold
AdjustedCostOfGoodsAndServicesSold
2300000
CY2019Q1 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
51
us-gaap Severance Costs1
SeveranceCosts1
3600000
us-gaap Payments For Postemployment Benefits
PaymentsForPostemploymentBenefits
3400000

Files In Submission

Name View Source Status
0001558370-19-007084-index-headers.html Edgar Link pending
0001558370-19-007084-index.html Edgar Link pending
0001558370-19-007084.txt Edgar Link pending
0001558370-19-007084-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tbph-20190630.xsd Edgar Link pending
tbph-20190630ex1017d2103.htm Edgar Link pending
tbph-20190630ex102a8169b.htm Edgar Link pending
tbph-20190630ex311fce379.htm Edgar Link pending
tbph-20190630ex3129eb423.htm Edgar Link pending
tbph-20190630x10q.htm Edgar Link pending
tbph-20190630x10q_htm.xml Edgar Link completed
tbph-20190630xex32.htm Edgar Link pending
tbph-20190630_cal.xml Edgar Link unprocessable
tbph-20190630_def.xml Edgar Link unprocessable
tbph-20190630_lab.xml Edgar Link unprocessable
tbph-20190630_pre.xml Edgar Link unprocessable
tbph20190630ex1017d2103001.jpg Edgar Link pending